Focal SegmentalGlomerulosclerosis Market – Drivers
As there is no drug approved forthe treatment of FSGS yet. Thus, limited treatment therapy and governmentfunding for research on rare diseases are expected to drive growth of the FocalSegmental Glomerulosclerosis Market. For instance, in 2015, the U.S. Foodand Drug Administration (FDA) and European Commission both granted Sparsentan,as orphan drug designation for the treatment of FSGS. This Sparsentan is anovel drug candidate with dual mechanism of action combines angiotensinreceptor blockade with endothelin receptor blockade and is currently beingevaluated in a Phase III trial, which expected to complete in December 2022.
Increasing research anddevelopment for FSGS drugs by various manufacturers is also fueling growth ofthe FSGS market. For instance, Pfizer Inc., is undergoing clinical trial forthe evaluation of its drug, PF-06730512 in adults with primary focal segmentalglomerulosclerosis. This drug is currently in Phase II study and is expected tocomplete in June 2021.
Focal SegmentalGlomerulosclerosis (FSGS) is a rare kidney disease affecting the kidney'sfiltering system (glomeruli) and resulting in serious scarring and end stagerenal disease. For instance, according to the article in Clinical Journal ofAmerican Society of Nephrology, 2017, FSGS incidence rates are often higher inmen, an estimated 1.5-fold higher as compared to women. FSGS is characterizedby symptoms such as edema, proteinuria, weight gain, increased cholesterol, andproteins in blood.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2224
Moreover, government investmentsinto the rare disease treatment is expected to drive the growth of market. Forinstance, according to an annual data report from the U.S. Renal Data System2017, Medicare invested around US$ 34 billion for people on dialysis withchronic kidney disease.
Focal Segmental GlomerulosclerosisMarket – Restraint
Lack of awareness amongpopulation regarding this disease and high cost of dialysis therapy mayrestrict growth of this market to some extent. For instance, according to anarticle published in University of Michigan 2017, awareness among patients withFSGS is considerably low when the patients are in primary stage of FSGS, whichis hampering growth of the FSGS market.
Focal Segmental GlomerulosclerosisMarket – Regional Analysis
On the basis of region, theglobal focal segmental glomerulosclerosis market is segmented into NorthAmerica, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected todominate the FSGS market due to high prevalence of FSGS along with chronickidney diseases. For instance, According to an annual data report by the U.S.Renal Data System 2017, the overall burden of kidney disease, kidney failurewith dialysis, and kidney transplantation is highest in U.S., thus driving thegrowth of the focal segmental glomerulosclerosis market.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/focal-segmental-glomerulosclerosis-market-2224
Asia Pacific region is expectedto witness significant growth in market due to collaboration agreements andpartnerships among various players. For instance, Oraxion Therapeutics, Inc., asubsidiary of Indian company Aten Porus, is undergoing preclinical and efficacystudy of the drug, ORX-301, which can be used in the treatment of FSGS. InFebruary 2018, Oraxion Therapeutics, Inc., entered into an Option Agreementwith the U.S-based Biopharmaceutical Company and under this agreement, U.S. basedcompany gets exclusive rights for further clinical studies and license of thisdrug in the U.S.
The key players operating in thefocal segmental glomerulosclerosis (FSGS) market include GlaxoSmithKline plc.,Novartis AG, Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Retrophin,Inc., AbbVie, Inc., Pfizer, Inc., AstraZeneca plc., Sanofi S.A, and Teva Pharmaceutical Industries Ltd.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2224
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
